The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Using Antibody-Drug Conjugates for Treatment of AML

Alexander E. Perl, MD
Published Online:4:22 PM, Tue November 20, 2018

Alexander E. Perl, MD, associate professor of medicine at the University of Pennsylvania, discusses the use of antibody-drug conjugates (ADC) in acute myeloid leukemia (AML). Gemtuzumab ozogamicin (Mylotarg) has already been approved for this patient population.

This agent was previously approved for relapsed disease, but withdrawn for single-agent use due to toxicity concerns.

Nonetheless, randomized data supported the use of this ADC in patients with AML. It is important to understand in which patients this treatment is most effective, which Perl notes as patients with relatively favorable chemotherapy-sensitive genotypes.

Perl adds that he has incorporated gemtuzumab ozogamicin as a standard therapy in his practice for patients with core binding factor-positive AML.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.